Do Alarmins Have a Role in Multiple Myeloma?

Area of Science:

• Oncology
• Immunology
• Biochemistry

Background:

• Alarmins like calprotectin (CLP), S100A6, and high mobility group nucleosome-binding protein 1 (HMGN1) are implicated in tumor pathogenesis.
• Understanding their role in multiple myeloma (MM) is crucial for diagnostic and prognostic insights.

Purpose of the Study:

• To investigate the association between serum CLP, S100A6, and HMGN1 levels and clinical/laboratory findings in MM patients.
• To explore the potential roles of these alarmins in MM pathogenesis.

Main Methods:

• Serum levels of CLP, S100A6, and HMGN1 were measured using sandwich ELISA in 55 newly diagnosed MM patients and 32 healthy controls.
• Medical records were reviewed, and statistical analyses, including ROC analysis, were performed.

Main Results:

• Serum CLP, S100A6, and HMGN1 levels were significantly lower in MM patients compared to controls.
• Diagnostic cut-off values were established for each biomarker.
• CLP levels were higher in light chain MM than heavy chain MM, with negative correlations observed between CLP and M protein, IgG, globulin, and beta-2 microglobulin.

Conclusions:

• Reduced serum CLP, S100A6, and HMGN1 levels are characteristic of newly diagnosed MM.
• Lower HMGN1 levels may be linked to genetic abnormalities in MM.
• CLP's potential binding to paraprotein in heavy chain MM could explain its decreased serum levels.